Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a PER.C6 license agreement with Ireland-based Tibotec Pharmaceuticals Ltd. The non-exclusive agreement allows Tibotec to use the PER.C6 cell line for research in the field of virology. Under the terms of the agreement, Tibotec will pay a research license fee, annual maintenance fees and milestone payments. Further financial details were not disclosed.
Biotech Intelligence (http://www.biotech-intelligence.com/html/html/b15f2a60aeeba2cebd4493de1e1c8441.html)